Study Finds Upadacitinib Is More Effective Than Abatacept for Hard-to-Treat Rheumatoid Arthritis But Has More Side Effects
A head-to-head study looked at how RA patients who didn’t do well on their first biologic fared when they switched to either upadacitinib (Rinvoq) or abatacept (Orencia).
Continue reading